30 Years of Restylane®: Reshaping the Aesthetics Field Through Science-Led, Patient-Centric Innovation


ZUG, Switzerland — Galderma (SIX: GALD), the pure-play dermatology category leader, celebrates 30 years since Restylane was launched in Europe as the first hyaluronic acid (HA) injectable.1 With HA closest to the skin’s own, Restylane is designed to deliver personalized, natural-looking outcomes that meet diverse patient needs across key areas of the face, décolletage, and hands.8,10,12,21-31 With three decades of innovation across technology, packaging, and treatment areas, Restylane remains at the forefront of innovation, evolving from its original NASHA®, technology into a comprehensive portfolio spanning three distinct technologies: NASHA HD™, NASHA®, and OBT™.1,8,21,22 Together, these technologies offer solutions ranging from firmer gels that provide contouring and structural support, to soft, flexible formulations that smooth facial lines and wrinkles for a more youthful look.8,12,21-31 The Restylane portfolio has most recently achieved EU Medical Device Regulation certification for the products created with NASHA HD™, NASHA®, and OBT™ technologies.12,23-29 As one of the world’s most rigorous medical device regulatory frameworks, the certification reinforces confidence in the strong safety profile, quality standards and scientific foundation behind the portfolio.32

“Restylane’s 30-year journey is a testament to Galderma’s enduring commitment to science-led innovation in aesthetics. Supported by extensive clinical experience – including more than 400,000 patients evaluated for safety – and robust real-world data, Restylane has helped define aesthetics, setting a high standard for safety, efficacy and natural-looking results since it launched as the first HA injectable three decades ago. With market penetration still relatively low, significant opportunities remain to expand adoption, and as we look to the future, we will continue to build on this foundation through innovation that reinforces the essential role of HA injectables in the future of aesthetics.”

BALDO SCASSELLATI SFORZOLINI, M.D., Ph.D.
GLOBAL HEAD OF R&D
GALDERMA

Expanding Restylane’s versatility to support tailored aesthetic outcomes
Restylane continues to expand treatment possibilities through new technologies, indications, and devices.



Source link

  • Related Posts

    Caseware Verity-Powered Risk Suggestion Agent Launches to Help Auditors Identify Engagement-Specific Risks

    Caseware is the leading global AI platform for accounting professionals, serving 23,000+ firms in over 130 countries. Caseware’s platform powers audit, financial reporting, and compliance workflows for firms of every…

    Continue reading
    The Great Accretion and the Great Depression

    A very old idea, returning with a vengeance: The Second Industrial Revolution sparked a wave of new products and industrial processes, fueling an optimistic Roaring Twenties. But did excitement about…

    Continue reading

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Kent Cricket – Simon Cook leaves after promotion for coaching return

    Kent Cricket – Simon Cook leaves after promotion for coaching return

    Why GTA Studio Co-Founder Is Avoiding GTA 6–And All Open-World Games

    Why GTA Studio Co-Founder Is Avoiding GTA 6–And All Open-World Games

    OpenAI Will Add A Digital Watermark To Text And Code Generated In The EU

    OpenAI Will Add A Digital Watermark To Text And Code Generated In The EU

    Caseware Verity-Powered Risk Suggestion Agent Launches to Help Auditors Identify Engagement-Specific Risks

    Former "American Idol" contestant proclaims his innocence during sentencing for wife's murder

    Former "American Idol" contestant proclaims his innocence during sentencing for wife's murder

    MLB playoff winners and losers: Yankees can’t handle Rays’ pressure, White Sox trade keeps paying off

    MLB playoff winners and losers: Yankees can’t handle Rays’ pressure, White Sox trade keeps paying off